Axima-CFR MALDI TOF Mass Spectrometer

描述（由申请人提供）：通过质谱法进行蛋白质序列分析的最新进展与大型蛋白质数据库的可用性相结合，为糖尿病研究创造了独特的机会。该申请要求获得矩阵辅助激光解吸电离飞行时间（MALDI TOF）质谱仪的资金，用于NIH资助的研究项目，目前正在进行的9名研究人员在乔斯林糖尿病中心。这些研究项目与1型和2型糖尿病有关，将在Joslin的5个研究部门进行。这些研究涉及糖尿病研究的许多领域，包括与1型糖尿病相关的自身免疫、胰岛素抵抗机制、2型糖尿病、肥胖、代谢和血管并发症。要求的特定仪器是Kratos Analytical生产的Axima-CFR MALDI TOF。该系统的特点包括单一同位素分辨率（>10000 Fwhm）、质量精度<10 ppm、灵敏度<10 fmol/mu l，以及独特的获得专利的曲线场反射器，能够产生无缝的源后衰变。该质谱仪的主要应用将是鉴定与糖尿病及其血管并发症相关的蛋白质表达和翻译后修饰的变化。在马萨诸塞州大学使用Axima-CFR进行的初步研究表明，该仪器对于本授权中描述的拟议用途非常有效。该仪器将由位于Joslin研究实验室中心的蛋白质组学核心实验室操作和维护。该仪器的使用率估计至少为90%，相当于参与该资助的9名研究者中的每一位每周约4小时。糖尿病研究尚未完全受益于现有质谱技术提供的信息。为这项资助而聚集的研究人员拥有可用的专业知识和研究模型，以及明确的需求，利用质谱蛋白质分析来鉴定治疗糖尿病及其血管并发症的新机制和靶点。

DESCRIPTION (provided by applicant): Recent advances in protein sequence analysis by mass spectroscopy combined with the availability of large protein databases have created unique opportunities in diabetes research. This application requests funds for the acquisition of a Matrix Assisted Laser Desorption Ionization Time-of Flight (MALDI TOF) mass spectrometer to be used for NIH-funded research projects that are currently underway by nine Investigators at the Joslin Diabetes Center. These research projects are relevant to both type 1 and type 2 diabetes, and will be carried out in 5 research sections at the Joslin. These studies address a number of areas of diabetes research, including autoimmunity related to type 1 diabetes, mechanisms of insulin resistance, type 2 diabetes, obesity, metabolism, and vascular complications. The specific instrument requested is the Axima-CFR MALDI TOF manufactured by Kratos Analytical. Features of this system include monoisotopic resolution (>10000 Fwhm), mass accuracy <10 ppm, sensitivity of <10 fmol/mu l, and a unique patented curve field reflectron that enables the generation of seamless post source decay. The primary applications for this mass spectrometer will be to identify changes in protein expression and post-translational modification relevant to diabetes and its vascular complications. Preliminary studies using the Axima-CFR at the University of Massachusetts have demonstrated that this instrument is highly effective for the proposed uses described in this grant. This instrument will be operated and maintained by a Proteomies Core Laboratory, centrally located among research laboratories at the Joslin. Usage of this instrument is estimated as at least 90%, corresponding to approximately 4 hours per week for each of the 9 investigators participating in this grant. Diabetes research has not yet fully benefited from the information available from current mass spectroscopic technologies. The Investigators assembled for this grant have the expertise and research models available, as well as the clear needs, to utilize mass spectroscopic protein analysis for the identification of novel mechanism and targets for the treatment of diabetes and it vascular complications.